Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism:26-Week Results From the Phase 3 PaTHway Trial

Autor: Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Claudio Marcocci, Bart L Clarke, Lisa G Abbott, Lorenz C Hofbauer, Lynn Kohlmeier, Susanne Pihl, Xuebei An, Walter Frank Eng, Alden R Smith, Jenny Ukena, Christopher T Sibley, Aimee D Shu, Lars Rejnmark

Publikováno v: Khan, A A, Rubin, M R, Schwarz, P, Vokes, T, Shoback, D M, Gagnon, C, Palermo, A, Marcocci, C, Clarke, B L, Abbott, L G, Hofbauer, L C, Kohlmeier, L, Pihl, S, An, X, Eng, W F, Smith, A R, Ukena, J, Sibley, C T, Shu, A D & Rejnmark, L 2023, ' Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism : 26-Week Results From the Phase 3 PaTHway Trial ', Journal of Bone and Mineral Research, vol. 38, no. 1, pp. 14-25 . https://doi.org/10.1002/jbmr.4726

Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology. PTH replacement therapy is the ideal physiologic treatment for hyp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598c72df8edf4f71a1305314e63ef0e2
https://pure.au.dk/portal/da/publications/efficacy-and-safety-of-parathyroid-hormone-replacement-with-transcon-pth-in-hypoparathyroidism(e24e64f1-bec4-43b6-9e7e-c0510d90c590).html